Oncobax immune treatment for advanced lung and kidney cancers
Part of Cancer, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests Oncobax®-AK, an immune-based treatment, in people with advanced (stage IV) non-squamous lung cancer or clear cell kidney cancer. It seeks to see if the treatment can help cancer respond better and whether it is safe for patients who meet specific immune and health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old.
- You have stage IV non-squamous NSCLC or clear cell kidney (renal) cancer confirmed by biopsy.
- Your lung cancer is currently stable disease on scan (iRECIST) and your tumor has high PD-L1 (greater than 50%).
- Your overall health is good enough to do daily activities (ECOG score 0–1).
- Your stool test is negative for Akkermansia.
- You have at least one measurable tumor spot on scans and blood tests are within limits (hemoglobin ≥ 100 g/L, albumin > 35 g/L).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests an experimental drug called AK138D1, either by itself or combined with another drug (ivonescimab), for people with advanced non-small cell lung cancer that has spread. It aims to see if these treatments are safe and effective.
This trial tests whether adding a probiotic (CBM588) to a standard immunotherapy combination (nivolumab and ipilimumab) helps treat advanced kidney cancer. It is for people with a specific type of kidney cancer that has spread or cannot be removed with surgery, who have not had systemic treatment before.
This trial tests a new immunotherapy drug, AK104, for people with stage III non-small cell lung cancer that cannot be removed with surgery. It is for those who have finished chemoradiotherapy and have not gotten worse.
This phase 1 trial tests a new drug called AK137, which is designed to help your immune system better attack cancer cells. It is for people with advanced tumors that have not been helped by standard therapies. The goal is to find out if AK137 is safe and effective.
This trial tests a new treatment for advanced large-cell neuroendocrine cancer of the lung, a rare type of lung cancer. You may qualify if you've had one round of standard chemotherapy and your cancer has not improved with other treatments.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.